Your browser is no longer supported. Please, upgrade your browser.
Settings
GHDX Genomic Health, Inc. daily Stock Chart
GHDX [NASD]
Genomic Health, Inc.
Index- P/E- EPS (ttm)-0.42 Insider Own2.00% Shs Outstand34.07M Perf Week-0.91%
Market Cap1.08B Forward P/E102.47 EPS next Y0.31 Insider Trans-11.66% Shs Float33.07M Perf Month6.87%
Income-13.90M PEG- EPS next Q-0.06 Inst Own91.10% Short Float2.78% Perf Quarter3.61%
Sales327.90M P/S3.28 EPS this Y59.30% Inst Trans0.15% Short Ratio7.00 Perf Half Y8.30%
Book/sh4.64 P/B6.80 EPS next Y2269.23% ROA-7.40% Target Price31.75 Perf Year35.04%
Cash/sh2.85 P/C11.09 EPS next 5Y5.50% ROE-9.70% 52W Range22.45 - 33.96 Perf YTD7.38%
Dividend- P/FCF- EPS past 5Y-29.50% ROI-10.80% 52W High-7.07% Beta0.46
Dividend %- Quick Ratio3.50 Sales past 5Y9.70% Gross Margin82.50% 52W Low40.58% ATR1.07
Employees846 Current Ratio3.50 Sales Q/Q10.10% Oper. Margin-4.70% RSI (14)59.44 Volatility3.30% 3.04%
OptionableYes Debt/Eq0.00 EPS Q/Q148.00% Profit Margin-4.20% Rel Volume0.38 Prev Close31.08
ShortableYes LT Debt/Eq0.00 EarningsFeb 14 AMC Payout- Avg Volume131.49K Price31.56
Recom2.60 SMA201.00% SMA507.58% SMA2009.05% Volume50,382 Change1.54%
Jan-18-17Initiated Deutsche Bank Hold $31
Feb-11-16Reiterated Canaccord Genuity Buy $44 → $38
Jan-11-16Downgrade Piper Jaffray Overweight → Neutral
Jan-07-16Reiterated Barclays Underweight $25 → $27
Jan-06-16Upgrade Canaccord Genuity Hold → Buy $26 → $44
Nov-23-15Upgrade UBS Neutral → Buy $29 → $38
Nov-04-15Upgrade Raymond James Mkt Perform → Outperform
Sep-02-15Initiated Barclays Underweight $25
Aug-28-15Upgrade Raymond James Underperform → Mkt Perform
Aug-05-15Reiterated Canaccord Genuity Hold $28 → $26
Mar-10-15Initiated UBS Neutral $34
Aug-11-14Reiterated Canaccord Genuity Hold $30 → $27
Aug-02-13Reiterated MLV & Co Hold $30 → $35
Feb-21-12Downgrade GARP Research Buy → Neutral
Feb-08-12Downgrade MLV & Co Buy → Hold $31.50 → $30
Dec-12-11Reiterated Ladenburg Thalmann Buy $26 → $32
Nov-02-11Upgrade Ladenburg Thalmann Neutral → Buy $26
Oct-11-11Reiterated RBC Capital Mkts Sector Perform $27 → $21
Oct-05-11Initiated Oppenheimer Perform $20
Feb-09-11Downgrade Ladenburg Thalmann Buy → Neutral
Mar-24-17 08:00AM  Published Outcomes Results from SEER Registries Indicates That Many Node-positive Breast Cancer Patients Can Avoid Chemotherapy Based on Oncotype DX® Results PR Newswire
Mar-22-17 09:11AM  Genomic Health's Cancer Test Business Strong, Expenses High
07:20AM  Genomic Health (GHDX) Up 2.1% Since Earnings Report: Can It Continue?
Mar-21-17 01:04PM  GENOMIC HEALTH INC Financials
08:34AM  Genomic Health's Breast Recurrence Test Data Encouraging
Mar-20-17 08:00AM  Multiple Presentations at 15th St. Gallen International Breast Cancer Conference Demonstrate Significant Impact of Oncotype DX Breast Recurrence Score® in Reducing Burden and Cost of Chemotherapy PR Newswire
Mar-15-17 04:30PM  GENOMIC HEALTH INC Files SEC form 10-K, Annual Report
Mar-07-17 01:23PM  The Best Bet in the Growing Genetic Testing Market: Genetic Health vs. Invitae at Motley Fool
Feb-28-17 08:00AM  Genomic Health to Present at the Cowen and Company 37th Annual Health Care Conference PR Newswire
Feb-24-17 09:24AM  3 Most Wildly Overvalued Stocks in Healthcare at Motley Fool
Feb-22-17 02:17PM  Genomic Health, Inc. :GHDX-US: Earnings Analysis: 2016 By the Numbers : February 22, 2017
Feb-21-17 07:11AM  Genomic Health, Inc. breached its 50 day moving average in a Bullish Manner : GHDX-US : February 21, 2017
Feb-16-17 11:05AM  Genomic Health, Inc. :GHDX-US: Earnings Analysis: Q4, 2016 By the Numbers : February 16, 2017 -8.42%
08:00AM  Four New Studies of Oncotype DX® Genomic Prostate Score (GPS) Reconfirm Value of Test in Guiding Early-stage Prostate Cancer Risk Assessment and Treatment Selection PR Newswire
Feb-15-17 07:34PM  Why Genomic Health Inc. Jumped Higher Today at Motley Fool +10.24%
04:17PM  Genomic Health, Inc. Swings to a Profit at Motley Fool
08:57AM  Genomic Health (GHDX) Earnings Surpass Estimates in Q4
Feb-14-17 09:26PM  Edited Transcript of GHDX earnings conference call or presentation 14-Feb-17 9:30pm GMT
05:05PM  Genomic Health tops 4Q profit forecasts
04:19PM  GENOMIC HEALTH INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibi
04:05PM  Genomic Health Announces 2016 Fourth Quarter and Year-End Financial Results, Provides 2017 Financial Outlook PR Newswire
07:07AM  Q4 2016 Genomic Health Inc Earnings Release - After Market Close
Feb-07-17 08:00AM  Genomic Health to Announce Fourth Quarter and Year-End 2016 Financial Results and Host Conference Call on Tuesday, February 14, 2017 PR Newswire
Jan-18-17 03:57PM  Coverage initiated on Genomic Health by Deutsche Bank
12:29PM  Deutsche Bank Optimistic On Fundamentals In Life Science Tools/Diagnostics Sector
Jan-14-17 12:10PM  Why Exact Sciences' Stock Could Go Much Higher at Motley Fool
Jan-03-17 08:00AM  Genomic Health to Present at the 35th Annual J.P. Morgan Healthcare Conference PR Newswire
Dec-22-16 08:00AM  Genomic Health Announces Inclusion of Oncotype DX® in the 8th Edition of American Joint Committee on Cancer (AJCC) Criteria for Breast Cancer Staging PR Newswire
Dec-20-16 07:38AM  Genomic Health, Inc. breached its 50 day moving average in a Bearish Manner : GHDX-US : December 20, 2016
Dec-15-16 04:25PM  GENOMIC HEALTH INC Files SEC form 8-K, Change in Directors or Principal Officers
Dec-14-16 11:29PM  Is Genomic Health, Inc. (GHDX) A Good Stock To Buy? at Insider Monkey
Dec-12-16 09:59AM  Genomic Health Posts Impressive Data for Oncotype DX Test
07:24AM  Will Endopredict Win Myriad's (MYGN) Genomic Testing War?
Dec-09-16 08:40AM  Genomic Health Announces Results from Multiple Oncotype DX® Studies, Reinforcing its Impact in Delivering Precision Medicine to Breast Cancer Patients Around the World PR Newswire
Dec-07-16 08:16AM  Genomic Health: Cancer Test Business Strong, Q3 Dismal
Dec-05-16 02:03PM  Genomic Health, Inc. Value Analysis (NASDAQ:GHDX) : December 5, 2016
Dec-02-16 11:20AM  Hedge Funds Begin to Sour on Kulicke and Soffa Industries Inc. (KLIC) at Insider Monkey
07:44AM  Genomic Health, Inc. breached its 50 day moving average in a Bearish Manner : GHDX-US : December 2, 2016
Nov-29-16 08:00AM  Genomic Health Announces Presentation of Multiple Oncotype DX® Studies at the 2016 CTRC-AACR San Antonio Breast Cancer Symposium, Reinforcing Value of Genomics in Precision Medicine PR Newswire
Nov-04-16 04:19PM  GENOMIC HEALTH INC Files SEC form 10-Q, Quarterly Report
Nov-03-16 10:23PM  Genomic Health, Inc.: Almost at Breakeven at Motley Fool
08:31AM  Genomic Health, Inc. breached its 50 day moving average in a Bearish Manner : GHDX-US : November 3, 2016
08:00AM  Genomic Health to Present at the Credit Suisse 25th Annual Healthcare Conference PR Newswire
Nov-02-16 09:26AM  Genomic Health (GHDX) Posts Wider-than-Expected Q3 Loss
Nov-01-16 07:42PM  Edited Transcript of GHDX earnings conference call or presentation 1-Nov-16 8:30pm GMT
06:02PM  Genomic Health reports 3Q loss
04:25PM  GENOMIC HEALTH INC Files SEC form 8-K, Termination of a Material Definitive Agreement, Results of Operations and Fina
04:05PM  Genomic Health Reports Third Consecutive Quarter of Double-Digit Revenue Growth in Announcement of Third Quarter 2016 Financial Results PR Newswire
04:04PM  Genomic Health Announces Positive Topline Clinical Validation Study Results Demonstrating Oncotype DX® Prostate Cancer Test Predicts Risk of Metastasis and Mortality PR Newswire
07:07AM  Q3 2016 Genomic Health Inc Earnings Release - After Market Close
Oct-26-16 09:15AM  Comprehensive Economic Analysis Published in Reviews in Urology Demonstrates Oncotype DX® Prostate Cancer Test Leads to Substantial Cost Savings and Increase in Active Surveillance PR Newswire
Oct-25-16 08:00AM  Genomic Health to Announce Third Quarter 2016 Financial Results and Host Conference Call on Tuesday, November 1, 2016 PR Newswire
Oct-13-16 01:00AM  This Innovative Healthcare Stock Belongs In My Portfolio -- What About Yours?
Oct-11-16 08:00AM  Genomic Health Presents Robust Analytical Validation Study Results of Oncotype SEQ Liquid Biopsy Mutation Panel PR Newswire
Oct-10-16 08:00AM  Multiple Oncotype DX® Presentations at ESMO 2016 Congress Reinforce Its Unique Clinical Utility with Prospective Outcomes Results in Over 63,000 Breast Cancer Patients PR Newswire
Sep-28-16 08:00AM  Genomic Health Reinforces Global Leadership in Genomic-based Diagnostics with Presentation of Nine Personalized Medicine Studies Conducted in Six Countries at ESMO 2016 Congress PR Newswire
Sep-20-16 11:47AM  Genomic Health, Inc. Value Analysis (NASDAQ:GHDX) : September 20, 2016
Sep-19-16 08:37AM  Genomic Health, Inc. breached its 50 day moving average in a Bearish Manner : GHDX-US : September 19, 2016
Sep-16-16 10:05AM  5 Stocks to Trade for Big Breakout Gains
Sep-14-16 10:08AM  ETFs with exposure to Genomic Health, Inc. : September 14, 2016
Sep-07-16 08:28AM  Genomic Health, Inc. breached its 50 day moving average in a Bullish Manner : GHDX-US : September 7, 2016
Aug-31-16 08:00AM  Genomic Health to Present at the 2016 Wells Fargo Healthcare Conference PR Newswire
Aug-24-16 05:01PM  [$$] Breast cancer test raises hope chemotherapy can be avoided at Financial Times
Aug-21-16 10:10AM  Huge 21st Century Fox Buy Highlights Insider Buying: Cavium, Akamai Technologies, Activision Blizzard and More at 24/7 Wall St.
Aug-16-16 12:19PM  ETFs with exposure to Genomic Health, Inc. : August 16, 2016
Aug-15-16 08:19AM  Genomic Health, Inc. breached its 50 day moving average in a Bearish Manner : GHDX-US : August 15, 2016
Aug-12-16 10:51AM  Genomic Health, Inc. :GHDX-US: Earnings Analysis: Q2, 2016 By the Numbers : August 12, 2016 -6.38%
Aug-09-16 05:18PM  GENOMIC HEALTH INC Files SEC form 10-Q, Quarterly Report
Aug-03-16 03:11PM  Genomic Health (GHDX) Q2 Loss Narrows Y/Y, Sales Beat
Aug-02-16 09:34PM  Edited Transcript of GHDX earnings conference call or presentation 2-Aug-16 8:30pm GMT
06:23PM  Genomic Health reports 2Q loss
04:11PM  GENOMIC HEALTH INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibi
04:05PM  Genomic Health Reports Continued Double-Digit Growth in Announcement of Second Quarter 2016 Financial Results, Raises Low End of Full-Year Test and Revenue Guidance PR Newswire
07:07AM  Q2 2016 Genomic Health Inc Earnings Release - After Market Close
Jul-26-16 08:00AM  Genomic Health to Announce Second Quarter 2016 Financial Results and Host Conference Call on Tuesday, August 2, 2016 PR Newswire
Jul-11-16 09:28AM  Genomic Health to Offer Epic Science's AR-V7 test, Shares Up
Jul-08-16 05:57PM  [$$] Test Aids Prostate Cancer Treatment at The Wall Street Journal
Jul-07-16 12:11AM  [$$] Test Aids Prostate Cancer Treatment at The Wall Street Journal
12:05AM  Genomic Health and Epic Sciences Announce Strategic Collaboration to Deliver Novel AR-V7 Liquid Biopsy Test to Predict Treatment Response in Metastatic Prostate Cancer PR Newswire
Jul-05-16 12:10PM  Genomic Health, Inc. Value Analysis (NASDAQ:GHDX) : July 5, 2016
Jul-04-16 08:17AM  Genomic Health, Inc. breached its 50 day moving average in a Bullish Manner : GHDX-US : July 4, 2016
Jun-24-16 08:50AM  Genomic Health: Can the Liquid Biopsy Test Boost Margins?
Jun-23-16 04:08PM  GENOMIC HEALTH INC Files SEC form 8-K, Change in Directors or Principal Officers
Jun-17-16 08:13AM  Genomic Health Brings Liquid Biopsy Test for Stage IV Cancer
Jun-15-16 05:21PM  GENOMIC HEALTH INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
Jun-14-16 08:00AM  Genomic Health Launches Oncotype SEQ Liquid Biopsy Mutation Panel PR Newswire
Jun-08-16 04:05PM  Nature Partner Journals Publish Five-year Outcomes Results from SEER Registry Demonstrating Oncotype DX® Accurately Identifies Early-stage Breast Cancer Patients with Excellent Survival PR Newswire
Jun-05-16 08:00AM  Genomic Health Announces Multiple Oncotype DX® Presentations at ASCO 2016 Showcasing Industry-leading Commitment to Bringing Precision Medicine to Cancer Patients PR Newswire
May-31-16 08:00AM  Genomic Health to Present at Jefferies 2016 Healthcare Conference PR Newswire
May-26-16 08:00AM  Genomic Health Announces Presentation of Seven Oncotype DX® Studies at the 2016 American Society of Clinical Oncology Annual Meeting, Including Additional Prospective Outcomes Analysis PR Newswire
May-25-16 08:00AM  Genomic Health Announces Publication in Journal of Clinical Oncology Demonstrating Oncotype DX® Predicts Late Distant Recurrence in Breast Cancer PR Newswire
May-24-16 08:25AM  Genomic Health (GHDX): Q1 Results Strong, Costs Escalate
May-19-16 07:29PM  ETFs with exposure to Genomic Health, Inc. : May 19, 2016
09:00AM  Genomic Health, Inc. breached its 50 day moving average in a Bearish Manner : GHDX-US : May 19, 2016
May-10-16 08:07PM  Genomic Health, Inc. Earnings: Waiting for (More) Reimbursement at Motley Fool
May-09-16 05:46PM  GENOMIC HEALTH INC Files SEC form 10-Q, Quarterly Report
10:59AM  Genomic Health, Inc. :GHDX-US: Earnings Analysis: Q1, 2016 By the Numbers
May-05-16 01:41PM  Correction: Earns-Genomic Health story +11.16%
12:48PM  Why Genomic Health, Inc. Earned a Higher Share Price at Motley Fool
09:05AM  Genomic Health, Inc. breached its 50 day moving average in a Bearish Manner : GHDX-US : May 5, 2016
Genomic Health, Inc., a healthcare company, provides actionable genomic information to personalize cancer treatment decisions in the United States and internationally. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions. The company offers the Oncotype DX invasive breast cancer test that is used for early stage invasive breast cancer patients to predict the likelihood of breast cancer recurrence and chemotherapy benefit. It also provides the Oncotype DX colon cancer test, which is used to predict the likelihood of colon cancer recurrence in patients with stage II disease, as well as for use in patients with stage III disease treated with oxaliplatin-containing adjuvant therapy. In addition, the company provides the Oncotype DX tests for patients with ductal carcinoma in situ, a pre-invasive form of breast cancer; and the Oncotype DX prostate cancer test, which provides a genomic prostate score to predict disease aggressiveness in men with low risk disease, as well as used to enhance treatment decisions for prostate cancer patients in conjunction with the Gleason score or tumor grading. Its development stage pipeline products include Oncotype SEQ product for use in the monitoring and management of various cancer types; and Oncotype TRACK products for non-invasive tumor monitoring. The company offers its products through a network of distributors. Genomic Health, Inc. was founded in 2000 and is based in Redwood City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Shak StevenChief Scientific OfficerMar 23Option Exercise23.315,000116,550336,103Mar 24 07:05 PM
Shak StevenChief Scientific OfficerMar 23Sale31.265,000156,295331,103Mar 24 07:05 PM
Leber LauraChief Communication OfficerMar 20Sale31.883,07297,94114,627Mar 22 04:03 PM
Cole G BradleyCOOMar 08Option Exercise23.315,610130,76945,338Mar 10 06:21 PM
Cole G BradleyCOOMar 08Sale31.555,710180,13439,528Mar 10 06:21 PM
Popovits Kimberly JPresident and CEOMar 06Option Exercise23.312906,76078,526Mar 07 08:34 PM
Popovits Kimberly JPresident and CEOMar 06Sale31.082909,01478,236Mar 07 08:34 PM
Popovits Kimberly JPresident and CEOMar 03Option Exercise23.314,710109,79082,946Mar 07 08:34 PM
Popovits Kimberly JPresident and CEOMar 03Sale31.094,710146,44078,236Mar 07 08:34 PM
Shak StevenChief Scientific OfficerFeb 23Option Exercise23.315,000116,550336,103Feb 27 09:56 PM
Shak StevenChief Scientific OfficerFeb 23Sale29.365,000146,815331,103Feb 27 09:56 PM
Febbo Phillip G.Chief Medical OfficerFeb 16Sale30.092,49575,06420,644Feb 17 06:44 PM
Cole G BradleyCOOFeb 15Option Exercise23.315,000116,55048,022Feb 17 06:43 PM
Cole G BradleyCOOFeb 15Sale29.005,000145,00043,022Feb 17 06:43 PM
Shak StevenChief Scientific OfficerJan 23Option Exercise23.315,000116,550332,207Jan 25 08:01 PM
Shak StevenChief Scientific OfficerJan 23Sale27.285,000136,387327,207Jan 25 08:01 PM
Cole G BradleyCOOJan 10Option Exercise23.315,000116,55040,882Jan 12 05:39 PM
Cole G BradleyCOOJan 10Sale29.225,000146,08735,882Jan 12 05:39 PM
Cole G BradleyCOODec 06Option Exercise23.315,000116,55040,882Dec 08 08:12 PM
Cole G BradleyCOODec 06Sale30.615,000153,03035,882Dec 08 08:12 PM
Popovits Kimberly JPresident and CEODec 05Option Exercise23.315,000116,55064,620Dec 06 07:17 PM
Popovits Kimberly JPresident and CEODec 05Sale30.025,000150,10059,620Dec 06 07:17 PM
Leber LauraChief Communication OfficerNov 21Option Exercise17.413,60062,67621,399Nov 23 02:43 PM
Leber LauraChief Communication OfficerNov 21Sale31.737,068224,26614,331Nov 23 02:43 PM
Shak StevenChief Scientific OfficerNov 10Option Exercise18.895,00094,450330,534Nov 15 04:56 PM
Shak StevenChief Scientific OfficerNov 10Sale31.715,000158,569327,207Nov 15 04:56 PM
Cole G BradleyCOONov 08Option Exercise23.315,000116,55040,426Nov 10 07:37 PM
Cole G BradleyCOONov 08Sale29.685,000148,42235,426Nov 10 07:37 PM
Popovits Kimberly JPresident and CEONov 03Option Exercise18.895,313100,36364,933Nov 07 06:53 PM
Popovits Kimberly JPresident and CEONov 03Sale28.885,313153,42359,620Nov 07 06:53 PM
Shak StevenChief Scientific OfficerOct 11Option Exercise18.895,00094,450332,207Oct 12 07:24 PM
Shak StevenChief Scientific OfficerOct 11Sale30.395,000151,925327,207Oct 12 07:24 PM
Cole G BradleyCOOOct 10Option Exercise21.188,290175,56039,716Oct 12 06:07 PM
Cole G BradleyCOOOct 10Sale30.598,290253,57235,426Oct 12 06:07 PM
Vaughn James JChief Commercial OfficerOct 06Sale29.683,00089,04226,079Oct 11 08:07 PM
Shak StevenChief Scientific OfficerSep 13Option Exercise18.895,00094,450332,207Sep 15 06:25 PM
Shak StevenChief Scientific OfficerSep 13Sale26.835,000134,156327,207Sep 15 06:25 PM
Cole G BradleyCOOSep 06Option Exercise18.894,00075,56039,426Sep 08 06:36 PM
Cole G BradleyCOOSep 06Sale27.414,000109,63735,426Sep 08 06:36 PM
Shak StevenChief Scientific OfficerAug 23Option Exercise18.895,00094,450332,207Aug 25 06:49 PM
Shak StevenChief Scientific OfficerAug 23Sale27.245,000136,215327,207Aug 25 06:49 PM
BAKER FELIXDirectorAug 15Buy27.02100,0002,701,59011,348,958Aug 15 06:02 PM
Cole G BradleyCOOAug 11Option Exercise18.895,00094,45040,426Aug 15 06:03 PM
Cole G BradleyCOOAug 11Sale28.875,000144,37435,426Aug 15 06:03 PM
Vaughn James JChief Commercial OfficerAug 08Sale28.743,00086,22229,079Aug 10 07:09 PM
Shak StevenChief Scientific OfficerJul 19Option Exercise18.895,00094,450332,207Jul 22 04:13 PM
Shak StevenChief Scientific OfficerJul 19Sale27.425,000137,111327,207Jul 22 04:13 PM
Cole G BradleyCOOJul 06Option Exercise18.895,00094,45040,426Jul 08 05:05 PM
Cole G BradleyCOOJul 06Sale26.645,000133,22335,426Jul 08 05:05 PM
Shak StevenChief Scientific OfficerJun 21Option Exercise18.895,00094,450332,207Jun 23 04:14 PM
Shak StevenChief Scientific OfficerJun 21Sale25.775,000128,859327,207Jun 23 04:14 PM
Cole G BradleyCOOJun 09Option Exercise18.895,00094,45040,426Jun 13 04:13 PM
Cole G BradleyCOOJun 09Sale26.625,000133,11835,426Jun 13 04:13 PM
Vaughn James JChief Commercial OfficerJun 06Option Exercise18.891,99737,72334,076Jun 08 04:49 PM
Vaughn James JChief Commercial OfficerJun 06Sale28.001,99755,91632,079Jun 08 04:49 PM
BAKER FELIXDirectorMay 17Option Exercise10.7349,500531,13511,258,316May 19 06:23 PM
Cole G BradleyCOOMay 16Option Exercise18.895,00094,45039,970May 18 07:34 PM
Cole G BradleyCOOMay 16Sale27.605,000137,99534,970May 18 07:34 PM
Febbo Phillip G.Chief Medical OfficerMay 10Sale27.206,324172,03415,013May 12 04:57 PM
Vaughn James JChief Commercial OfficerMay 09Option Exercise18.892,00037,78033,255May 11 04:42 PM
Vaughn James JChief Commercial OfficerMay 09Sale28.002,00056,00031,255May 11 04:42 PM
Shak StevenChief Scientific OfficerMay 04Option Exercise18.8910,000188,900336,383May 06 06:13 PM
Shak StevenChief Scientific OfficerMay 04Sale25.4310,000254,296326,383May 06 06:13 PM